Phase II Trial of Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders


Phase II Trial of Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Andrew M Evens, DO, MSc (2/12/14)
Duvic M et al. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Proc ASH 2013;Abstract 367.

Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.